Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS. DeMichele A, et al. Among authors: mcroy l. Breast Cancer Res. 2021 Mar 24;23(1):37. doi: 10.1186/s13058-021-01409-8. Breast Cancer Res. 2021. PMID: 33761995 Free PMC article.
Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
Kish JK, Ward MA, Garofalo D, Ahmed HV, McRoy L, Laney J, Zanotti G, Braverman J, Yu H, Feinberg BA. Kish JK, et al. Among authors: mcroy l. Breast Cancer Res. 2018 May 2;20(1):37. doi: 10.1186/s13058-018-0958-2. Breast Cancer Res. 2018. PMID: 29720233 Free PMC article. Clinical Trial.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, Shparyk YV, Thummala A, Voitko N, Bananis E, McRoy L, Wilner K, Huang X, Kim S, Slamon DJ, Ettl J. Finn RS, et al. Among authors: mcroy l. Breast Cancer Res Treat. 2020 Sep;183(2):419-428. doi: 10.1007/s10549-020-05755-7. Epub 2020 Jul 18. Breast Cancer Res Treat. 2020. PMID: 32683565 Free PMC article. Clinical Trial.
Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.
Maculaitis MC, Liu X, Will O, Hanson M, McRoy L, Berk A, Crastnopol M. Maculaitis MC, et al. Among authors: mcroy l. Patient Prefer Adherence. 2020 Nov 5;14:2201-2214. doi: 10.2147/PPA.S254934. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 33177814 Free PMC article.
A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application.
Richardson D, Zhan L, Mahtani R, McRoy L, Mitra D, Reynolds M, Odom D, Hollis K, Kaye JA, Jones C, Hargis J. Richardson D, et al. Among authors: mcroy l. Breast Cancer Res Treat. 2021 May;187(1):113-124. doi: 10.1007/s10549-020-06082-7. Epub 2021 Jan 11. Breast Cancer Res Treat. 2021. PMID: 33428072 Free PMC article.
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
Rugo HS, Cristofanilli M, Loibl S, Harbeck N, DeMichele A, Iwata H, Park YH, Brufsky A, Theall KP, Huang X, McRoy L, Bananis E, Turner NC. Rugo HS, et al. Among authors: mcroy l. Oncologist. 2021 Aug;26(8):e1339-e1346. doi: 10.1002/onco.13833. Epub 2021 Jun 12. Oncologist. 2021. PMID: 34037282 Free PMC article. Clinical Trial.
46 results